Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17730184 | 1.00 | DRD4 (0.48) | DRD4GPR139CTSLCTSBCTSK | |
| SCHEMBL17730039 | 0.87 | AR (0.56) | CTSLCTSBCTSKNAMPTMAOA | |
| SCHEMBL17730038 | 0.87 | AR (0.56) | CTSLCTSBCTSKNAMPTMAOA | |
| SCHEMBL4400995 | 0.87 | MEN1 (0.52) | DRD4GPR139CTSLCTSBCTSK | |
| SCHEMBL17730182 | 0.82 | CRHR1 (0.58) | MEN1KMT2AMAOAKCNH2DRD2 | |
| SCHEMBL17730181 | 0.82 | CRHR1 (0.58) | MEN1KMT2AMAOAKCNH2DRD2 | |
| SCHEMBL4390094 | 0.80 | MAPK14 (0.50) | GPR139ACACBVNN1NAMPTMEN1 | |
| SCHEMBL4013506 | 0.79 | GAA (0.48) | GPR139ACACBVNN1NAMPTMEN1 | |
| SCHEMBL17818371 | 0.77 | MEN1 (0.56) | DRD4ACACBMEN1KMT2ADRD2 | |
| SCHEMBL5368326 | 0.76 | TPSAB1 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-3215142-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | DRD4 2693/4885GPR139 2909/4885CTSL 3780/4885 |
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | DRD4 2693/4885GPR139 2909/4885CTSL 3780/4885 |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | DRD4 2693/4885GPR139 2909/4885CTSL 3780/4885 |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | DRD4 2693/4885GPR139 2909/4885CTSL 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.